RB Capital Increases Investment in Sunshine Biopharma
April 22, 2021 08:00 ET | Source: Sunshine Biopharma Inc. Sunshine Biopharma Inc. Montreal, Quebec, CANADA
MONTREAL, April 22, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug development program. In addition, RB Capital has provided the Company with assurances that it will continue to provide funding over the next 30 days for the Company’s other R&D activities, including Ada-27a anticancer drug.
Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are very pleased to continue our relationship with RB Capital as long-term investor in the Company. They truly understand our vision and are prepared to help us
Published: Apr 22, 2021
MONTREAL, April 22, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma, Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that RB Capital has injected an additional investment of $500,000 to augment the Company’s Coronavirus drug development program. In addition, RB Capital has provided the Company with assurances that it will continue to provide funding over the next 30 days for the Company’s other R&D activities, including Ada-27a anticancer drug.
Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are very pleased to continue our relationship with RB Capital as long-term investor in the Company. They truly understand our vision and are prepared to help us reach our exciting drug development objectives.”
(2)
MONTREAL, QC / ACCESSWIRE / January 14, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company s flagship anticancer compound targeted for pancreatic cancer.
Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, As a company, we continue to forge forward in our development of a COVID treatment and our anticancer compounds. This investment capital has been integral to our progress in each of these sectors.
Sunshine Biopharma Receives Fourth Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.